Next Article in Journal
Deep Multi-Objective Learning from Low-Dose CT for Automatic Lung-RADS Report Generation
Next Article in Special Issue
Initiation Timing of Continuous Interscalene Brachial Plexus Blocks in Patients Undergoing Shoulder Arthroplasty: A Retrospective Before-and-After Study
Previous Article in Journal
The Sequential Change in Left Ventricular Function among Various Cardiovascular Diseases: A 12-Year Study
Previous Article in Special Issue
Perioperative Magnesium for Postoperative Analgesia: An Umbrella Review of Systematic Reviews and Updated Meta-Analysis of Randomized Controlled Trials
 
 
Article
Peer-Review Record

Effect of Flumazenil on Emergence Agitation after Orthognathic Surgery: A Randomized Controlled Trial

J. Pers. Med. 2022, 12(3), 416; https://doi.org/10.3390/jpm12030416
by Young Hyun Koo 1, Geun Joo Choi 1, Hyun Kang 1, Yong Hun Jung 1, Young Cheol Woo 1, Young-Jun Choi 2 and Chong Wha Baek 1,*
Reviewer 1: Anonymous
Reviewer 2:
J. Pers. Med. 2022, 12(3), 416; https://doi.org/10.3390/jpm12030416
Submission received: 6 January 2022 / Revised: 24 February 2022 / Accepted: 3 March 2022 / Published: 7 March 2022

Round 1

Reviewer 1 Report

This RCT aims to compare the incidence of emergence agitation after othognatic surgery under sevoflurane anaesthesia with/ without consecutive administration of flumazenil. Secondary goal is the comparison of quantitative parameters (time periods) during recovery from anaesthesia.

The present study focusses on clinical aspects and potential benefits of flumazenil administration after sevoflurane anaesthesia. This approach seems to be conclusive, as there is some evidence on this topic, which the authors have correctly pointed out. The particular benefits of reducing the incidence of emergence agitation in context of orthognatic surgery are outlined clearly in the manuscript. The authors' conclusions are appropriate to the design, the findings, and the discussion in the present study.

 

Specific comments:

L. 158-160: according to the statistical analysis, there is no significant difference; thus the manuscript should not suggest that the incidence in flumazenil group was lower; perhaps the wording "seemed to be lower" might be more appropriate;

L.295-299: this passage appears to be difficult to understand; I can't see a clear statement/ message here; consider editing the wording or avoiding this part of the text (L. 297 - it has to read "significantly");

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 2 Report

On P3L107 - Not clear why the study syringes need to be handed to the outcome assessor - appears like the study drug is given at the same time as reversal and antiemetic administration by the anesthesia provider - If such is the design of the study, then the outcome assessor's role need just be to assess the recovery profile, not handle or administer the drug. Ideally the assessor should only enter after the study drug administration.

P3L140: Not sure what is intended by the statement that the primary measure outcome is sample size. Instead please rephrase that the intent is to estimate sample size or power calculation

Author Response

Please see the attachment

Author Response File: Author Response.docx

Back to TopTop